Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 4/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | USP2 | O75604 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7557900 | 0.98 | GLA (0.56) | GLARAB9AL3MBTL1LMNATSHR | |
| SCHEMBL7555206 | 0.98 | GLA (0.56) | GLARAB9AL3MBTL1LMNATSHR | |
| SCHEMBL7557661 | 0.98 | GLA (0.56) | GLARAB9AL3MBTL1LMNATSHR | |
| SCHEMBL7551563 | 0.98 | GLA (0.56) | GLARAB9AL3MBTL1LMNATSHR | |
| SCHEMBL294490 | 0.98 | GLA (0.56) | GLARAB9AL3MBTL1LMNATSHR | |
| SCHEMBL294529 | 0.94 | GLA (0.59) | GLARAB9AL3MBTL1LMNATSHR | |
| SCHEMBL9415751 | 0.90 | GLA (0.67) | GLARAB9AL3MBTL1LMNATSHR | |
| SCHEMBL7694058 | 0.88 | GLA (0.65) | GLARAB9AL3MBTL1LMNATSHR | |
| SCHEMBL295077 | 0.86 | L3MBTL1 (0.55) | GLARAB9AL3MBTL1LMNATSHR | |
| SCHEMBL5452859 | 0.82 | GLA (0.59) | GLARAB9AL3MBTL1LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004056353-A2 | DEVICE AND METHOD FOR DELIVERING MMP INHIBITORS | NOVARTIS AG (CH) | 2004-07-08 | — | — | WO | claimed |
| US-20140031334-A1 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-01-30 | — | — | US | disclosed |
| US-8598162-B2 | Derivatives of 4-piperazin-1-yl-4-benzo[B]thiophene suitable for the treatment of CNS disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-12-03 | — | — | US | disclosed |
| EP-1389611-B1 | 20-HYDROXYEICOSATETRAENOIC ACID PRODUCTION INHIBITORS | TAISHO PHARMACEUTICAL CO LTD (JP) | 2012-06-27 | — | — | EP | disclosed |
| EP-2287161-B1 | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of CNS disorders | OTSUKA PHARMA CO LTD (JP) | 2012-05-09 | — | — | EP | disclosed |
| EP-2287162-B1 | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of CNS disorders | OTSUKA PHARMA CO LTD (JP) | 2012-05-09 | — | — | EP | disclosed |
| EP-2284169-B1 | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of CNS disorders | OTSUKA PHARMA CO LTD (JP) | 2012-03-14 | — | — | EP | disclosed |
| US-20120028920-A1 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. | 2012-02-02 | — | — | US | disclosed |
| EP-1919907-B9 | HETEROCYCLIC COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2012-01-18 | — | — | EP | disclosed |
| US-8071600-B2 | Derivatives of 4-piperazin-1-yl-4-benzo[B]thiophene suitable for the treatment of CNS disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-12-06 | — | — | US | disclosed |
| WO-2003075959-A1 | MATRIX METALLOPROTEINASE INHIBITORS IN COMBINATION WITH HYPOTHERMIA AND/OR RADIOTHERAPY FOR THE TREATMENT OF CANCER | NOVARTIS AG (CH) | 2003-09-18 | — | — | WO | disclosed |
| US-6500983-B2 | FOR THERAPY OF DISEASES OR CONDITIONS MEDIATED BY OVER-PRODUCTION OF OR OVER-RESPONSIVENESS TO TUMOR NECROSIS FACTOR (TNF) | NOVARTIS AG (CH) | 2002-12-31 | — | — | US | disclosed |
| EP-0929517-B1 | HYDROXAMIC ACID DERIVATIVES | NOVARTIS AG (CH) | 2002-06-12 | — | — | EP | disclosed |
| US-20020038045-A1 | Hydroxamic acid derivatives | NOVARTIS AG (CH) | 2002-03-28 | — | — | US | disclosed |
| EP-0929517-A1 | HYDROXAMIC ACID DERIVATIVES | Novartis AG (CH) | 1999-07-21 | — | — | EP | disclosed |
| WO-1998014424-A1 | HYDROXAMIC ACID DERIVATIVES | NOVARTIS AG (CH) | 1998-04-09 | — | — | WO | disclosed |
| CN-1114834-A | antidiabetic agent | OTSUKA PHARMA CO LTD (JP) | 1996-01-10 | — | — | CN | disclosed |
| EP-0670831-A1 | QUINOXALINE DERIVATIVE AS ANTIDIABETIC AGENT | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-09-13 | — | — | EP | disclosed |
| WO-1995009159-A1 | QUINOXALINE DERIVATIVE AS ANTIDIABETIC AGENT | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1995-04-06 | — | — | WO | disclosed |
| EP-0392317-A2 | Benzimidazoles, drugs containing these compounds and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1990-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028920-A1 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | GRIN2C, GRIN2B, PMP22 | GLA 4312/4885RAB9A 1250/4885L3MBTL1 1941/4885 |
| US-20140031334-A1 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | GRIN2C, GRIN2B, PMP22 | GLA 4312/4885RAB9A 1250/4885L3MBTL1 1941/4885 |
| US-20020038045-A1 | Hydroxamic acid derivatives | TNF, HCAR2, HCAR1 | GLA 288/4885RAB9A 3650/4885L3MBTL1 4396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.